{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:01:03Z","timestamp":1793109663775,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/15\/82\/31824"],"award-info":[{"award-number":["FS\/15\/82\/31824"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1093\/eurheartj\/ehy013","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T17:32:36Z","timestamp":1515691956000},"page":"1078-1085","source":"Crossref","is-referenced-by-count":135,"title":["Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy"],"prefix":"10.1093","volume":"39","author":[{"given":"Wael","family":"Sumaya","sequence":"first","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds v\u00e4g 38, SE-752 37 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds v\u00e4g 38, SE-752 37 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Siegbahn","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds v\u00e4g 38, SE-752 37 Uppsala, Sweden"},{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Gabrysch","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds v\u00e4g 38, SE-752 37 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bertilsson","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds v\u00e4g 38, SE-752 37 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Himmelmann","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi A","family":"Ajjan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"key\n\t\t\t\t20180626051803_ehy013-B1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) bleeding score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2017.01.010","article-title":"Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes","volume":"186","author":"Ducrocq","year":"2017","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B7","doi-asserted-by":"crossref","first-page":"e000021","DOI":"10.1136\/openhrt-2013-000021","article-title":"Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis","volume":"1","author":"Kwok","year":"2014","journal-title":"Open Heart"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":". 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B12","doi-asserted-by":"crossref","first-page":"e71150","DOI":"10.1371\/journal.pone.0071150","article-title":"Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure","volume":"8","author":"Neergaard-Petersen","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1160\/TH11-11-0760","article-title":"Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction","volume":"107","author":"Leander","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/ATVBAHA.109.194936","article-title":"Altered plasma fibrin clot properties are associated with in-stent thrombosis","volume":"30","author":"Undas","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B15","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/ATVBAHA.111.236786","article-title":"Clot architecture is altered in abdominal aortic aneurysms and correlates with aneurysm size","volume":"31","author":"Scott","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1479164110383723","article-title":"Coagulation and fibrinolysis in diabetes","volume":"7","author":"Alzahrani","year":"2010","journal-title":"Diab Vasc Dis Res"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MBC.0b013e32833a9035","article-title":"The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome","volume":"21","author":"Undas","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","article-title":"Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk","volume":"16","author":"Kearney","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B19","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3109\/09537104.2013.842965","article-title":"Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study","volume":"25","author":"Storey","year":"2014","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B22","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","article-title":"Heritability of clot formation, morphology, and lysis: the EuroCLOT study","volume":"27","author":"Carter","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1160\/th15-06-0467","article-title":"Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study","volume":"115","author":"Franchi","year":"2016","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00125-014-3267-z","article-title":"Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3","volume":"57","author":"Hess","year":"2014","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/eurheartj\/ehv491","article-title":"Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study","volume":"37","author":"Hagstrom","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1373\/clinchem.2011.171520","article-title":"Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study","volume":"58","author":"Akerblom","year":"2012","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B27","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/hmg\/ddw012","article-title":"Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome","volume":"25","author":"Johansson","year":"2016","journal-title":"Hum Mol Genet"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1160\/TH14-01-0032","article-title":"Fibrin clot properties and their modulation in thrombotic disorders","volume":"112","author":"Undas","year":"2014","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B29","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B30","first-page":"457","article-title":"Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention","volume":"117","author":"Christopoulos","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B31","first-page":"426","article-title":"Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention","volume":"117","author":"Kreutz","year":"2016","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B32","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B33","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","article-title":"Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B34","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"Undas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B36","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B37","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1210\/jc.2011-2894","article-title":"Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals","volume":"97","author":"Hooper","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/oby.2000.33","article-title":"Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults\u2013the ARIC study. Atherosclerosis risk in communities","volume":"8","author":"Duncan","year":"2000","journal-title":"Obes Res"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B39","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa011053","article-title":"The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes","volume":"345","author":"de Lemos","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180626051803_ehy013-B40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/07420529109059170","article-title":"Circadian variation of fibrinolytic activity in blood","volume":"8","author":"Andreotti","year":"1991","journal-title":"Chronobiol Int"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/13\/1078\/25085574\/ehy013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T04:19:59Z","timestamp":1570594799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/13\/1078\/4829678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,29]]},"references-count":40,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2018,1,29]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehy013","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2018,1,29]]}}}